2022
Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder
Na PJ, Ralevski E, Jegede O, Wolfgang A, Petrakis IL. Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder. Frontiers In Psychiatry 2022, 12: 768318. PMID: 35058816, PMCID: PMC8765227, DOI: 10.3389/fpsyt.2021.768318.Peer-Reviewed Original ResearchPost-traumatic stress disorderAlcohol use disorderCo-occurring depressionHeavy drinking daysBetter drinking outcomesDrinking daysDiagnostic groupsDrinking outcomesDepressive symptomsUse disordersPercent heavy drinking daysPercent drinking daysRandomized control trialSerotonergic antidepressantsPTSD comorbidityControl trialDepression groupDepressive outcomesSignificant interactionOverall significant differenceDesipramineParoxetinePlaceboMedicationsComorbid MDD
1990
A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply